Actively Recruiting

Phase Not Applicable
Age: 18Years +
All Genders
NCT07350564

Intensive Versus Conventional Blood Pressure Control Following Stroke Thrombectomy

Led by Hao Yonggang · Updated on 2026-01-20

910

Participants Needed

1

Research Sites

165 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

This clinical trial aims to investigate the safety and efficacy of intensive blood pressure lowering after successful reperfusion with thrombectomy in patients with acute anterior circulation large artery occlusive stroke. The main questions it aims to answer are: What is the optimal blood pressure range after revascularization with thrombectomy in patients with cerebral embolism? Can intensive blood pressure lowering improve outcomes in cerebral embolism patients following thrombectomy? Participants will be randomly assigned to either the intervention group, which receives stricter blood pressure control (systolic blood pressure target \<120 mmHg), or the control group, which follows a conventional blood pressure management approach (systolic blood pressure target 140-180 mmHg). Outcomes will be assessed during a 3-month follow-up period.

CONDITIONS

Official Title

Intensive Versus Conventional Blood Pressure Control Following Stroke Thrombectomy

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Age 18 years or older
  • Scheduled to receive endovascular thrombectomy within 24 hours after symptom onset
  • Diagnosed with acute anterior circulation ischemic stroke
  • National Institutes of Health Stroke Scale (NIHSS) score of 30 or less
  • Alberta Stroke Program Early CT Score (ASPECTS) of 6 or higher
  • Confirmed occlusion of the intracranial internal carotid artery or M1/M2 segment of the middle cerebral artery by imaging
  • Successful recanalization of the occluded vessel without in-situ or proximal stenosis (mTICI score 2b or higher)
  • Sustained elevated systolic blood pressure of 140 mmHg or higher for at least two consecutive measurements within 3 hours of reperfusion
  • Written informed consent provided by the patient or legal representative
Not Eligible

You will not qualify if you...

  • Pre-existing stroke disability with modified Rankin score greater than 2
  • Unlikely to benefit from or tolerate endovascular thrombectomy, including severe allergic reactions to contrast agents
  • Failure to achieve mTICI score 2b or higher or presence of in situ or proximal vascular stenosis
  • Contraindications to antihypertensive medications, such as allergies
  • Intracranial space-occupying lesions like brain tumors or vascular malformations
  • Severe liver dysfunction (ALT or AST more than 3 times the upper limit of normal)
  • Severe kidney dysfunction (serum creatinine above 3.0 mg/dL or GFR below 30 mL/min/1.73 m2) or dialysis
  • Serious illness with life expectancy less than 6 months
  • Lactating women
  • Participation in other interventional clinical trials within the last 3 months
  • Any condition making the patient unsuitable for study participation or unable to complete study procedures, including psychiatric, cognitive, emotional, or physical impairments

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

The Fourth Affiliated Hospital of Soochow University

Suzhou, Jiangsu, China, 215000

Actively Recruiting

Loading map...

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here